Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-01

AUTHORS

Phil McEwan, Simon Dixon, Keshwar Baboolal, Pete Conway, Craig J. Currie

ABSTRACT

Introduction: Immunosuppressive therapy is required to prevent graft rejection. Calcineurin inhibitors such as tacrolimus are paradoxically toxic to the kidney, whereas sirolimus (rapamycin; Rapamune®) is not generally associated with the nephrotoxicity of CNIs. The purpose of this study was to evaluate the relative cost utility of sirolimus versus tacrolimus for the primary prevention of graft rejection in renal transplant recipients in the UK.Methods: A stochastic simulation model was constructed using clinical trial and observational data comparing the two treatments. Time duration was up to 20 years. Costs were from a UK NHS perspective, valued at 2003 prices and discounted at 6%. Benefits were discounted at 1.5%. Simulated events included patient and graft survival, haemodialysis, peritoneal dialysis, re-transplants and acute rejection. Costs were summed for events and various maintenance therapies. Utility was differentially accredited depending upon survival and using the alternative renal replacement therapies. Outcome was predicted using post-transplant creatinine levels up to 3 years. Extensive statistical economic and sensitivity analyses were undertaken.Results: Over the 10-year horizon, sirolimus gained 0.72 years (discounted) of functioning graft over tacrolimus, resulting in an incremental cost per year of functioning graft that was dominant. Over a 20-year time horizon, the cost effectiveness of sirolimus over tacrolimus further improved with an average discounted gain in years of a functioning graft of 1.8 years, resulting in an incremental cost-utility ratio that was also dominant. The number of haemodialysis events was 48 243 for sirolimus recipients versus 127 829 for those receiving tacrolimus and peritoneal dialysis events 40 872 versus 105 249, respectively. Similar values were obtained when real-life observational data on tacrolimus use in Cardiff, Wales were entered into the model. Using data from Cardiff, sirolimus remained dominant over tacrolimus under all scenarios.Conclusion: Our study suggests that sirolimus may be more cost effective than tacrolimus for the primary prevention of graft rejection in renal transplant recipients in the UK. Sirolimus was economically ‘dominant’ under almost all scenarios investigated. This finding was robust using statistical economic analysis and univariate sensitivity analysis. More... »

PAGES

67-79

References to SciGraph publications

  • 1995-08. Health-related quality of life in endstage renal failure in QUALITY OF LIFE RESEARCH
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00019053-200624010-00006

    DOI

    http://dx.doi.org/10.2165/00019053-200624010-00006

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1046638930

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16445304


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Economics", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Applied Economics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Graft Rejection", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunosuppressive Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sirolimus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tacrolimus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "United Kingdom", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "School of Mathematics, Cardiff University, Cardiff, Wales, UK", 
              "id": "http://www.grid.ac/institutes/grid.5600.3", 
              "name": [
                "School of Mathematics, Cardiff University, Cardiff, Wales, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McEwan", 
            "givenName": "Phil", 
            "id": "sg:person.01346767345.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "School of Health and Related Research, University of Sheffield, Sheffield, England, UK", 
              "id": "http://www.grid.ac/institutes/grid.11835.3e", 
              "name": [
                "School of Health and Related Research, University of Sheffield, Sheffield, England, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dixon", 
            "givenName": "Simon", 
            "id": "sg:person.0677313420.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677313420.84"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Renal Medicine, University Hospital of Wales, Cardiff, Wales, UK", 
              "id": "http://www.grid.ac/institutes/grid.241103.5", 
              "name": [
                "Department of Renal Medicine, University Hospital of Wales, Cardiff, Wales, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Baboolal", 
            "givenName": "Keshwar", 
            "id": "sg:person.01227566136.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227566136.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Health Economics, Wyeth Laboratories-UK, Maidenhead, England, UK", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Health Economics, Wyeth Laboratories-UK, Maidenhead, England, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Conway", 
            "givenName": "Pete", 
            "id": "sg:person.01260313721.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260313721.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, University of Wales College of Medicine, Cardiff, Wales, UK", 
              "id": "http://www.grid.ac/institutes/grid.5600.3", 
              "name": [
                "Department of Medicine, University of Wales College of Medicine, Cardiff, Wales, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Currie", 
            "givenName": "Craig J.", 
            "id": "sg:person.0673223071.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673223071.96"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf01593889", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012686417", 
              "https://doi.org/10.1007/bf01593889"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2006-01", 
        "datePublishedReg": "2006-01-01", 
        "description": "Introduction: Immunosuppressive therapy is required to prevent graft rejection. Calcineurin inhibitors such as tacrolimus are paradoxically toxic to the kidney, whereas sirolimus (rapamycin; Rapamune\u00ae) is not generally associated with the nephrotoxicity of CNIs. The purpose of this study was to evaluate the relative cost utility of sirolimus versus tacrolimus for the primary prevention of graft rejection in renal transplant recipients in the UK.Methods: A stochastic simulation model was constructed using clinical trial and observational data comparing the two treatments. Time duration was up to 20 years. Costs were from a UK NHS perspective, valued at 2003 prices and discounted at 6%. Benefits were discounted at 1.5%. Simulated events included patient and graft survival, haemodialysis, peritoneal dialysis, re-transplants and acute rejection. Costs were summed for events and various maintenance therapies. Utility was differentially accredited depending upon survival and using the alternative renal replacement therapies. Outcome was predicted using post-transplant creatinine levels up to 3 years. Extensive statistical economic and sensitivity analyses were undertaken.Results: Over the 10-year horizon, sirolimus gained 0.72 years (discounted) of functioning graft over tacrolimus, resulting in an incremental cost per year of functioning graft that was dominant. Over a 20-year time horizon, the cost effectiveness of sirolimus over tacrolimus further improved with an average discounted gain in years of a functioning graft of 1.8 years, resulting in an incremental cost-utility ratio that was also dominant. The number of haemodialysis events was 48 243 for sirolimus recipients versus 127 829 for those receiving tacrolimus and peritoneal dialysis events 40 872 versus 105 249, respectively. Similar values were obtained when real-life observational data on tacrolimus use in Cardiff, Wales were entered into the model. Using data from Cardiff, sirolimus remained dominant over tacrolimus under all scenarios.Conclusion: Our study suggests that sirolimus may be more cost effective than tacrolimus for the primary prevention of graft rejection in renal transplant recipients in the UK. Sirolimus was economically \u2018dominant\u2019 under almost all scenarios investigated. This finding was robust using statistical economic analysis and univariate sensitivity analysis.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00019053-200624010-00006", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1102812", 
            "issn": [
              "1170-7690", 
              "1179-2027"
            ], 
            "name": "PharmacoEconomics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "24"
          }
        ], 
        "keywords": [
          "renal transplant recipients", 
          "graft rejection", 
          "transplant recipients", 
          "primary prevention", 
          "alternative renal replacement therapy", 
          "renal replacement therapy", 
          "incremental cost-utility ratio", 
          "cost-utility ratio", 
          "UK NHS perspective", 
          "univariate sensitivity analysis", 
          "real-life observational data", 
          "acute rejection", 
          "tacrolimus use", 
          "immunosuppressive therapy", 
          "graft survival", 
          "maintenance therapy", 
          "renal transplantation", 
          "creatinine levels", 
          "calcineurin inhibitors", 
          "replacement therapy", 
          "NHS perspective", 
          "peritoneal dialysis", 
          "clinical trials", 
          "tacrolimus", 
          "sirolimus", 
          "cost utility", 
          "cost effectiveness", 
          "graft", 
          "therapy", 
          "incremental cost", 
          "recipients", 
          "prevention", 
          "survival", 
          "years", 
          "rejection", 
          "immunosuppression", 
          "nephrotoxicity", 
          "haemodialysis", 
          "transplantation", 
          "patients", 
          "kidney", 
          "CNI", 
          "trials", 
          "dialysis", 
          "outcomes", 
          "events", 
          "treatment", 
          "study", 
          "duration", 
          "inhibitors", 
          "sensitivity analysis", 
          "UK", 
          "utility", 
          "findings", 
          "data", 
          "Cardiff", 
          "levels", 
          "evaluation", 
          "similar values", 
          "effectiveness", 
          "benefits", 
          "analysis", 
          "observational data", 
          "use", 
          "purpose", 
          "time horizon", 
          "number", 
          "Wales", 
          "ratio", 
          "gain", 
          "stochastic simulation model", 
          "cost", 
          "time duration", 
          "economic analysis", 
          "model", 
          "values", 
          "perspective", 
          "scenarios", 
          "horizon", 
          "simulated events", 
          "simulation model", 
          "prices", 
          "nephrotoxicity of CNIs", 
          "relative cost utility", 
          "post-transplant creatinine levels", 
          "average discounted gain", 
          "discounted gain", 
          "haemodialysis events", 
          "sirolimus recipients", 
          "peritoneal dialysis events 40 872", 
          "dialysis events 40 872", 
          "events 40 872", 
          "statistical economic analysis"
        ], 
        "name": "Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK", 
        "pagination": "67-79", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1046638930"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00019053-200624010-00006"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16445304"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00019053-200624010-00006", 
          "https://app.dimensions.ai/details/publication/pub.1046638930"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_415.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00019053-200624010-00006"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200624010-00006'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200624010-00006'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200624010-00006'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200624010-00006'


     

    This table displays all metadata directly associated to this object as RDF triples.

    242 TRIPLES      22 PREDICATES      132 URIs      123 LITERALS      18 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00019053-200624010-00006 schema:about N037c0bc161cf4256a529dfe81a585510
    2 N2eb71df7c2ee4f62937a3d16515b942a
    3 N744c9a0d415b45f3917841504aa0f67d
    4 N7982eb76d9574d468e7e4816e956ccc9
    5 N8cb56341abd34aa2af14187e5a632015
    6 Na69a4b04bd3c478d89bc1edf5003bd5d
    7 Nb2a8e00d15584f58b7f267ea0c579393
    8 Nb5b840f63bac488ca07c395b302a2dd6
    9 Nc28bdf27bc894596b1c0041aa1d597a3
    10 Ncc778d26ca0f4bb69fa142d72984bf77
    11 Nd0c66bc016834b61b0b64f8165586b98
    12 anzsrc-for:14
    13 anzsrc-for:1402
    14 schema:author N8fc6d1dc6ccd4bd686cbd192c7bf829c
    15 schema:citation sg:pub.10.1007/bf01593889
    16 schema:datePublished 2006-01
    17 schema:datePublishedReg 2006-01-01
    18 schema:description Introduction: Immunosuppressive therapy is required to prevent graft rejection. Calcineurin inhibitors such as tacrolimus are paradoxically toxic to the kidney, whereas sirolimus (rapamycin; Rapamune®) is not generally associated with the nephrotoxicity of CNIs. The purpose of this study was to evaluate the relative cost utility of sirolimus versus tacrolimus for the primary prevention of graft rejection in renal transplant recipients in the UK.Methods: A stochastic simulation model was constructed using clinical trial and observational data comparing the two treatments. Time duration was up to 20 years. Costs were from a UK NHS perspective, valued at 2003 prices and discounted at 6%. Benefits were discounted at 1.5%. Simulated events included patient and graft survival, haemodialysis, peritoneal dialysis, re-transplants and acute rejection. Costs were summed for events and various maintenance therapies. Utility was differentially accredited depending upon survival and using the alternative renal replacement therapies. Outcome was predicted using post-transplant creatinine levels up to 3 years. Extensive statistical economic and sensitivity analyses were undertaken.Results: Over the 10-year horizon, sirolimus gained 0.72 years (discounted) of functioning graft over tacrolimus, resulting in an incremental cost per year of functioning graft that was dominant. Over a 20-year time horizon, the cost effectiveness of sirolimus over tacrolimus further improved with an average discounted gain in years of a functioning graft of 1.8 years, resulting in an incremental cost-utility ratio that was also dominant. The number of haemodialysis events was 48 243 for sirolimus recipients versus 127 829 for those receiving tacrolimus and peritoneal dialysis events 40 872 versus 105 249, respectively. Similar values were obtained when real-life observational data on tacrolimus use in Cardiff, Wales were entered into the model. Using data from Cardiff, sirolimus remained dominant over tacrolimus under all scenarios.Conclusion: Our study suggests that sirolimus may be more cost effective than tacrolimus for the primary prevention of graft rejection in renal transplant recipients in the UK. Sirolimus was economically ‘dominant’ under almost all scenarios investigated. This finding was robust using statistical economic analysis and univariate sensitivity analysis.
    19 schema:genre article
    20 schema:inLanguage en
    21 schema:isAccessibleForFree false
    22 schema:isPartOf N582b83c15f7442079b16c26b5acd4d26
    23 Nae2f53774ab94cb0bbccb7feef64c032
    24 sg:journal.1102812
    25 schema:keywords CNI
    26 Cardiff
    27 NHS perspective
    28 UK
    29 UK NHS perspective
    30 Wales
    31 acute rejection
    32 alternative renal replacement therapy
    33 analysis
    34 average discounted gain
    35 benefits
    36 calcineurin inhibitors
    37 clinical trials
    38 cost
    39 cost effectiveness
    40 cost utility
    41 cost-utility ratio
    42 creatinine levels
    43 data
    44 dialysis
    45 dialysis events 40 872
    46 discounted gain
    47 duration
    48 economic analysis
    49 effectiveness
    50 evaluation
    51 events
    52 events 40 872
    53 findings
    54 gain
    55 graft
    56 graft rejection
    57 graft survival
    58 haemodialysis
    59 haemodialysis events
    60 horizon
    61 immunosuppression
    62 immunosuppressive therapy
    63 incremental cost
    64 incremental cost-utility ratio
    65 inhibitors
    66 kidney
    67 levels
    68 maintenance therapy
    69 model
    70 nephrotoxicity
    71 nephrotoxicity of CNIs
    72 number
    73 observational data
    74 outcomes
    75 patients
    76 peritoneal dialysis
    77 peritoneal dialysis events 40 872
    78 perspective
    79 post-transplant creatinine levels
    80 prevention
    81 prices
    82 primary prevention
    83 purpose
    84 ratio
    85 real-life observational data
    86 recipients
    87 rejection
    88 relative cost utility
    89 renal replacement therapy
    90 renal transplant recipients
    91 renal transplantation
    92 replacement therapy
    93 scenarios
    94 sensitivity analysis
    95 similar values
    96 simulated events
    97 simulation model
    98 sirolimus
    99 sirolimus recipients
    100 statistical economic analysis
    101 stochastic simulation model
    102 study
    103 survival
    104 tacrolimus
    105 tacrolimus use
    106 therapy
    107 time duration
    108 time horizon
    109 transplant recipients
    110 transplantation
    111 treatment
    112 trials
    113 univariate sensitivity analysis
    114 use
    115 utility
    116 values
    117 years
    118 schema:name Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK
    119 schema:pagination 67-79
    120 schema:productId N23ea4683946740e3b0e4dd3c3c49f109
    121 N3dee2d93adc44cf08d801a96b6878430
    122 Nf041a02b1f06431eabf9bc0a55a0769e
    123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046638930
    124 https://doi.org/10.2165/00019053-200624010-00006
    125 schema:sdDatePublished 2021-12-01T19:17
    126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    127 schema:sdPublisher N02d80608f0e34468aa1811a08df04540
    128 schema:url https://doi.org/10.2165/00019053-200624010-00006
    129 sgo:license sg:explorer/license/
    130 sgo:sdDataset articles
    131 rdf:type schema:ScholarlyArticle
    132 N02bef792e3b44cfbae10999097b2a39b rdf:first sg:person.01227566136.23
    133 rdf:rest Nac1909fb7db149908de04502d41bacff
    134 N02d80608f0e34468aa1811a08df04540 schema:name Springer Nature - SN SciGraph project
    135 rdf:type schema:Organization
    136 N037c0bc161cf4256a529dfe81a585510 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Kidney Transplantation
    138 rdf:type schema:DefinedTerm
    139 N23ea4683946740e3b0e4dd3c3c49f109 schema:name pubmed_id
    140 schema:value 16445304
    141 rdf:type schema:PropertyValue
    142 N2eb71df7c2ee4f62937a3d16515b942a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Humans
    144 rdf:type schema:DefinedTerm
    145 N3dee2d93adc44cf08d801a96b6878430 schema:name dimensions_id
    146 schema:value pub.1046638930
    147 rdf:type schema:PropertyValue
    148 N582b83c15f7442079b16c26b5acd4d26 schema:issueNumber 1
    149 rdf:type schema:PublicationIssue
    150 N744c9a0d415b45f3917841504aa0f67d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Male
    152 rdf:type schema:DefinedTerm
    153 N7982eb76d9574d468e7e4816e956ccc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Immunosuppressive Agents
    155 rdf:type schema:DefinedTerm
    156 N8cb56341abd34aa2af14187e5a632015 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name United Kingdom
    158 rdf:type schema:DefinedTerm
    159 N8fc6d1dc6ccd4bd686cbd192c7bf829c rdf:first sg:person.01346767345.38
    160 rdf:rest Ne54363ea6cd047c38a2203321e45cf12
    161 Na69a4b04bd3c478d89bc1edf5003bd5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Graft Rejection
    163 rdf:type schema:DefinedTerm
    164 Nac1909fb7db149908de04502d41bacff rdf:first sg:person.01260313721.08
    165 rdf:rest Nd40da2ff88444df9ae1095c1188b5068
    166 Nae2f53774ab94cb0bbccb7feef64c032 schema:volumeNumber 24
    167 rdf:type schema:PublicationVolume
    168 Nb2a8e00d15584f58b7f267ea0c579393 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Cost-Benefit Analysis
    170 rdf:type schema:DefinedTerm
    171 Nb5b840f63bac488ca07c395b302a2dd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Female
    173 rdf:type schema:DefinedTerm
    174 Nc28bdf27bc894596b1c0041aa1d597a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Sirolimus
    176 rdf:type schema:DefinedTerm
    177 Ncc778d26ca0f4bb69fa142d72984bf77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Tacrolimus
    179 rdf:type schema:DefinedTerm
    180 Nd0c66bc016834b61b0b64f8165586b98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Adult
    182 rdf:type schema:DefinedTerm
    183 Nd40da2ff88444df9ae1095c1188b5068 rdf:first sg:person.0673223071.96
    184 rdf:rest rdf:nil
    185 Ne54363ea6cd047c38a2203321e45cf12 rdf:first sg:person.0677313420.84
    186 rdf:rest N02bef792e3b44cfbae10999097b2a39b
    187 Nf041a02b1f06431eabf9bc0a55a0769e schema:name doi
    188 schema:value 10.2165/00019053-200624010-00006
    189 rdf:type schema:PropertyValue
    190 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
    191 schema:name Economics
    192 rdf:type schema:DefinedTerm
    193 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
    194 schema:name Applied Economics
    195 rdf:type schema:DefinedTerm
    196 sg:journal.1102812 schema:issn 1170-7690
    197 1179-2027
    198 schema:name PharmacoEconomics
    199 schema:publisher Springer Nature
    200 rdf:type schema:Periodical
    201 sg:person.01227566136.23 schema:affiliation grid-institutes:grid.241103.5
    202 schema:familyName Baboolal
    203 schema:givenName Keshwar
    204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227566136.23
    205 rdf:type schema:Person
    206 sg:person.01260313721.08 schema:affiliation grid-institutes:None
    207 schema:familyName Conway
    208 schema:givenName Pete
    209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260313721.08
    210 rdf:type schema:Person
    211 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.5600.3
    212 schema:familyName McEwan
    213 schema:givenName Phil
    214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
    215 rdf:type schema:Person
    216 sg:person.0673223071.96 schema:affiliation grid-institutes:grid.5600.3
    217 schema:familyName Currie
    218 schema:givenName Craig J.
    219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673223071.96
    220 rdf:type schema:Person
    221 sg:person.0677313420.84 schema:affiliation grid-institutes:grid.11835.3e
    222 schema:familyName Dixon
    223 schema:givenName Simon
    224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677313420.84
    225 rdf:type schema:Person
    226 sg:pub.10.1007/bf01593889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012686417
    227 https://doi.org/10.1007/bf01593889
    228 rdf:type schema:CreativeWork
    229 grid-institutes:None schema:alternateName Health Economics, Wyeth Laboratories-UK, Maidenhead, England, UK
    230 schema:name Health Economics, Wyeth Laboratories-UK, Maidenhead, England, UK
    231 rdf:type schema:Organization
    232 grid-institutes:grid.11835.3e schema:alternateName School of Health and Related Research, University of Sheffield, Sheffield, England, UK
    233 schema:name School of Health and Related Research, University of Sheffield, Sheffield, England, UK
    234 rdf:type schema:Organization
    235 grid-institutes:grid.241103.5 schema:alternateName Department of Renal Medicine, University Hospital of Wales, Cardiff, Wales, UK
    236 schema:name Department of Renal Medicine, University Hospital of Wales, Cardiff, Wales, UK
    237 rdf:type schema:Organization
    238 grid-institutes:grid.5600.3 schema:alternateName Department of Medicine, University of Wales College of Medicine, Cardiff, Wales, UK
    239 School of Mathematics, Cardiff University, Cardiff, Wales, UK
    240 schema:name Department of Medicine, University of Wales College of Medicine, Cardiff, Wales, UK
    241 School of Mathematics, Cardiff University, Cardiff, Wales, UK
    242 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...